Experimental drug ADCT-301 tested in just 3 patients – study halted early
NCT ID NCT04639024
First seen May 12, 2026 · Last updated May 24, 2026 · Updated 4 times
Summary
This study tested a drug called ADCT-301 in people whose blood cancer (AML, MDS, or related conditions) came back after a stem cell transplant. Only 3 people took part before the study was stopped early. The goal was to see if the drug is safe and can help achieve remission. Risks included low blood cell counts, weight loss, and a rare nerve condition called Guillain-Barre syndrome.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Duke University Health System
Durham, North Carolina, 27705, United States
Conditions
Explore the condition pages connected to this study.